



OmniComm Systems, Inc. (HQ)
2101 W Commercial Boulevard, Suite 3500
Fort Lauderdale, FL 33309 (USA)
Phone: +1 (954) 473-1254
Fax: +1 (954) 473-1256
www.omnicomm.com

FOR IMMEDIATE RELEASE

CONTACT:

Kuno van der Post M.Sc., Ph.D
OmniComm Systems, Inc.
954-473-1254
kvanderpost@omnicomm.com

DSP Clinical Selects OmniComm's TrialMaster® EDC Solution for Upcoming Trial
OmniComm's innovative technology generates efficiencies and streamlines operations across each stage of the clinical trial

Fort Lauderdale, FL, October 16, 2013 – OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that DSP Clinical, an OmniComm Preferred Program CRO partner since 2011, has selected OmniComm's innovative TrialMaster EDC system for their latest early phase trial.

"Our sponsors appreciate our use of an EDC solution that is nimble enough to manage early phase studies, but robust and flexible enough to handle complex later phase studies as well," commented Darlene Panzitta, President and Founder of DSP Clinical. "OmniComm's integrated and intuitive technology, coupled with their dedication to first-class service, aligns perfectly with our needs."

The OmniComm TrialMaster EDC Suite is a comprehensive, functionally-rich solution designed to simplify clinical trial processes. Featuring proprietary, proven workflows, the TrialMaster system enables enhanced efficiencies and streamlined clinical operations across each stage of the trial. OmniComm's EDC solutions have been used in over 3,800 clinical trials across the globe.

"We share DSP's commitment to deliver operational excellence to clients," said Stephen Johnson, President & COO of OmniComm Systems. "By incorporating innovative features such as our award winning SDTM custom export utility, risked-based monitoring, and centralized monitoring with auto-redaction into TrialMaster, our CRO partners can offer advanced technology that meets the critical needs of their sponsors for high quality study data in a more timely and cost effective manner."

OmniComm Systems, Inc.
1100 Cornwall Road, Suite 111
Monmouth Junction, NJ 08852
Phone: +1 (732) 960-2820
Fax: +1 (732) 297-3055

OmniComm Europe GmbH
Kaiserstrasse 139-141
53113 Bonn / Germany
Phone: +49 (0) 228 22744 0
Fax: +49 (0) 228 22744 19

OmniComm, Ltd
Medino House
Rushington Business Park
Southampton SO40 9LU, UK
Office +44 (0) 1590 608 001



OmniComm Systems, Inc. (HQ)
2101 W Commercial Boulevard, Suite 3500
Fort Lauderdale, FL 33309 (USA)
Phone: +1 (954) 473-1254
Fax: +1 (954) 473-1256
www.omnicomm.com

About DSP Clinical

DSP Clinical (www.dspclinical.com) is a full-service CRO that manages all aspects of Phase I to IV clinical studies for small to mid-size pharmaceutical, biotechnology, and device companies. DSP Clinical's therapeutic expertise focuses on women's health, infertility, endocrinology, urology and pain. The organization offers services including overall project management, study site management, study and site monitoring, data management (including Electronic Data Capture), statistics, medical writing, and FDA submissions.

About OmniComm Systems

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

###